Cellular Depletion of Biomolecular Targets

Technology #32372

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
ClpXP unfolds and degrades protein substrates. Proteins bearing a degradation peptide (red) are recognized by ClpX (blue), unfolded and processively translocated through the pore of ClpP (green) where degradation occurs. ATP hydrolysis provides the unfolding and translocation energy.
Categories
Researchers
Sean Moore, Ph. D.
Managed By
Brion Berman
Assistant Director 407.882.0342
Patent Protection

Cellular depletion of biomolecular targets

US Patent 9,243,280

Of the ~4,400 Escherichia coli (E. coli) open reading frames, roughly a third have not had their encoded protein functions experimentally verified. This collection of genes creates a significant black box in our understanding of fundamental cellular physiology, especially when considering those genes of unknown function that are essential for viability. Much of what is known about gene function has followed from studies in bacteria where there are suites of powerful tools available that have been refined in model systems such as E. coli. Despite astounding advances in DNA sequencing and synthesis technologies, there is a remaining fundamental question that has piqued the interest of hundreds of investigators: what are the minimal requirements for life? The predominant approaches to answering this question have been to either computationally compare genomes and identify conserved core genes, or to randomly disrupt the genomes using transposons and deduce which genes do not tolerate interruption. These combined strategies form the cornerstone of our understanding of what comprises an essential genome.

Technical Details

This invention focuses on a new method of testing the function and essentialness of certain proteins. By bonding certain peptide tags to pre-selected proteins, the processive protease within the cell targets and degrades the protein of interest. Degradation can be induced by activating the proteolytic activity, either by induction of the protease, induction of an adapter for the protease, or by addition of the protease to mixtures, allowing for the creation of novel cell physiologies. Cells lacking a putative drug target can be generated for comparative studies or for control experiments. Additionally, cell extracts or macromolecular assemblies can be generated that lack a specific component even if that component is necessary for the formation of the original complex.

Looking for Partners

Looking for partners to commercialize for research purposes and test/validate for preclinical use.

Benefits

  • Tests multifunctional proteins more effectively
  • Removes second site mutation complications

Applications

  • Protein degradation
  • Understanding diseases